

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited (the “Stock Exchange”) take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



天津泰達生物醫學工程股份有限公司
Tianjin TEDA Biomedical Engineering Company Limited
(a joint stock company incorporated in the People’s Republic of China with limited liability)
(Stock code: 8189)

PROFIT WARNING

This announcement is made pursuant to Rule 17.10(2)(a) of the Rules Governing the Listing of Securities on GEM of The Stock Exchange of Hong Kong Limited (the “**GEM Listing Rules**”) and the Inside Information Provisions (as defined under the GEM Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The board of directors (the “**Board**”) of Tianjin TEDA Biomedical Engineering Company Limited (the “**Company**”) wishes to inform the shareholders of the Company and potential investors that, based on the information currently available, including but not limited to the consolidated results of the Company and its subsidiaries (collectively, the “**Group**”), the Group is expected to incur a loss attributable to shareholders for the year ended 31 December 2018 as compared with the loss of RMB21,283,684 for the year ended 31 December 2017.

The Group will incur a significant loss for the year ended 31 December 2018. Such loss is mainly due to the fact that the quantitative EEG detection business was not developed as expected as a result of the changes in operating environment. Hence, it is expected to make an impairment provision of its substantial intangible assets during the year.

The Company is still in the process of finalising the annual results of the Group. The information contained in this announcement is only based on the preliminary assessment by the Board according to the estimated annual results of the Group and, therefore, the audited annual results may differ from the information contained in this announcement. Details of the annual results will be published by the end of March 2019.

Shareholders and potential investors of the Company are urged to exercise caution when dealing in the shares of the Company.

By order of the Board
Tianjin TEDA Biomedical Engineering Company Limited
Sun Li
Chairman

Tianjin, the PRC
13 March 2019

As at the date of this announcement, the executive Directors of the Company are Sun Li, Hao Zhihui and He Xin; the non-executive Directors of the Company are Cao Aixin, Li Ximing and Gai Li; the independent non-executive Directors of the Company are Li Xudong, Wang Yongkang and Gao Chun.

This announcement, for which the directors are willing to collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief that the information contained in this announcement is accurate and complete in all material respects and is not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this announcement misleading.

This announcement will remain on the GEM website at <http://www.hkgem.com> on the “Latest Company Announcements” page for 7 days from the date of its posting, and it will also be published and remain on the website of the Company at www.bioteda.com.